Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Therapeutics for Diabetic Retinopathy_EyeGene Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
EG-Mirotin: First-in-Class recombinant polypeptide novel subcutaneous drug containing RGD-motif targeted to suppress edema and vascular leakage for Non-proliferative Diabetic Retinopathy (NPDR)...
Contact Heajin Jung
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
EG-Mirotin, a human recombinant protein, stabilizes and normalizes abnormal and partially damaged blood vessels. The mechanistic action of EG-Mirotin not only treats the fundamental symptoms of early

1. Summary

• EG-Mirotin is a RGD-motif containing human recombinant polypeptide (compound name: EGT022 / 58 amino acids / MW: 6.1-kDa).

• First in Class novel subcutaneous drug targeted to suppress edema and vascular leakage in abnormal retinal microvasculature through that normalization and stabilization of damaged retinal microvasculature.

• Pre-clinical toxicity studies were successfully completed both in-house and in Europe (Switzerland) with no signs of toxicity and/or genotoxicity. Additional studies confirmed there were no undesirable angiogenesis and effects on tumor growth. Pre-clinical efficacy studies were conducted in both the Oxygen-Induced Retinopathy model and Streptozotocin-induced diabetic rat model. Retinal flat mount and angiography results have demonstrated formation of stabilized and mature retinal vasculature, and Optical Coherence Tomography (OCT) measurements have shown a statistically significant reduction in macular edema.

• Phase I safety studies conducted in Europe (Netherlands) was successful. Treatment with EG-Mirotin in single and multiple doses was well tolerated in all subjects (both healthy and diabetic patients).

• Phase IIa proof-of-concept studies are currently being conducted in Europe (France).

2. Applications

• EGT022 and its potential applications



3. Market Feasibility

Incidence and prevalence of Diabetic Retinopathy (Global)

• Recent studies have shown that there were approximately 220 million people with diabetes globally (either diagnosed or undiagnosed) in 2009; Latest WHO statistics have this figure at 347 million as of 2012

• Current prevalence of DR – both NPDR and PDR – is over 100 million worldwide

• 74.7mn estimated with early stage DR symptoms or NPDR

(Source: Visiongain 2010)

4. Technical Advantages

• Laser Photocoagulation has been widely used to treat eye diseases, but only covers Proliferative Diabetic Retinopathy and Age-related Macular Degeneration. Drugs such as anti-VEGF and steroids are available, but vary in efficacy/side effects, and are usually for late-stage Diabetic Retinopathy.

• First in Class novel subcutaneous therapeutic for Non-proliferative Diabetic Retinopathy that is competitive in terms of both route of administration and cost versus current alternate treatments.

5. Technical Highlighted Summary

• Novel sub-cutaneous therapeutic for Diabetic Retinopathy (Non-proliferative Diabetic Retinopathy / NPDR)

• Targeted to suppress edema and vascular leakage in abnormal capillaries in NPDR patients

EG-Mirotin vs. marketed drugs

Company Name EyeGene Roche Regeneron

Product Name EG-Mirotin Lucentis Eylea

Compound EGT022

(recombinant polypeptide) Ranibizumab

(monoclonal antibody) Aflibercept

(recombinant fusion protein)

Mechanism Normalization and stabilization of retinal vasculature Anti-VEGF preventing retinal neovascularization VEGF-trap preventing retinal neovascularization

Indication NPDR, DR, DME wAMD, DME, RVO wAMD, DME, RVO

Manufacturing Pichia pastoris E. coli CHO K1

Route of Administration Subcutaneous Injection (non-invasive) Intravitreal Injection (invasive) Intravitreal Injection (invasive)

Dosage 1mg or 2mg wAMD : 0.5mg

DME : 0.3mg wAMD : 2.0mg

DME : 2.0mg

Dosing Regimen 5 daily subcutaneous injections Once a month (every 28 days) Once a month (every 4 weeks)

Side Effects general disorders and administration site conditions, NO systemic side effect reported in Phase 1 safety studies conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension

Treatment Cost Approximately 50% of

marketed products $2,000 per injection $1,850 per injection

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
• Available for out-licensing • Seeking co-development, Strategic partnerships
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE